Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Group 1 - Jaguar Health, Inc. has entered into a U.S. licensing agreement with Future Pak, LLC, making Future Pak the exclusive marketer for Mytesi and Canalevia-CA1 [1] - The agreement includes an $18 million upfront payment to Jaguar, consisting of $16 million upon deal closing and $2 million upon completion of post-closing conditions [1] - Future Pak may provide up to an additional $20 million in milestone and other future payments [1] Group 2 - Mytesi is an FDA-approved drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy [1] - Canalevia-CA1 is a prescription drug for the treatment of chemotherapy-induced diarrhea in dogs [1] - Jaguar will continue to manufacture Mytesi and Canalevia-CA1, allowing the company to focus on its rare-disease pipeline and ongoing business development discussions with potential partners [1]